ulcer
coliti
uc
chronic
idiopath
inflammatori
diseas
character
relaps
remit
mucos
inflamm
colon
uc
patient
experi
least
one
sever
exacerb
requir
hospit
sever
uc
suc
potenti
lifethreaten
condit
defin
six
bloodi
stool
per
day
plu
least
one
follow
truelov
witt
criteria
fever
temperatur
tachycardia
puls
rate
bpm
anemia
hemoglobin
normal
elev
erythrocyt
sediment
rate
esr
mmh
intraven
corticosteroid
remain
firstlin
therapi
suc
report
reduc
mortal
rate
howev
patient
diseas
steroidrefractori
requir
invas
treatment
overal
colectomi
rate
suc
patient
higher
accord
cohort
studi
howev
case
fail
respons
steroid
therapi
stool
frequenc
stoolsd
stoolsd
togeth
creactiv
protein
crp
mgl
day
colectomi
rate
salvag
therapi
either
infliximab
cyclosporin
appear
improv
clinic
outcom
case
steroid
therapi
failur
random
control
trial
patient
respond
intens
medic
therapi
sever
complic
includ
toxic
megacolon
perfor
sever
hemorrhag
consid
time
surgeri
delay
surgeri
associ
increas
mortal
higher
risk
postop
complic
therefor
paramount
import
assess
respons
therapi
regularli
use
standard
criteria
initi
optim
therapi
option
promptli
effect
manag
suc
remain
great
challeng
china
asian
countri
experienc
increas
incid
preval
uc
longterm
followup
studi
hong
kong
report
sixfold
increas
incid
uc
per
per
wang
et
al
analyz
uc
patient
hospit
hospit
mainland
china
note
steadi
increas
number
case
patient
identifi
sever
bibliometr
analys
literatur
review
scholarli
public
chines
period
databas
provid
epidemiolog
inform
exampl
comprehens
search
chines
biomed
literatur
databas
retriev
articl
relat
inflammatori
bowel
diseas
ibd
publish
chines
medic
journal
case
uc
report
number
report
case
steadili
increas
annual
accord
jiang
et
al
chines
paper
regard
uc
publish
patient
uc
report
given
dramat
increas
uc
databas
survey
public
analys
requir
collat
avail
inform
recent
epidemiolog
treatment
efficaci
uc
suc
china
addit
epidemiolog
inform
bibliometr
analys
provid
perspect
research
hotspot
exampl
accord
ouyang
et
al
articl
basic
research
ibd
china
rapidli
increas
predominantli
focus
immunolog
mechan
moreov
bibliometr
analysi
indic
includ
public
output
research
complex
wide
use
assess
perform
research
program
institut
andor
countri
mention
china
wit
increas
incid
preval
uc
furthermor
china
popul
account
total
world
popul
comprehens
studi
quantiti
qualiti
sucrel
chines
public
desper
need
studi
aim
perform
bibliometr
analysi
determin
tempor
trend
number
chines
public
uc
suc
assess
suc
research
perform
studi
also
aim
provid
review
data
treatment
type
efficaci
suc
patient
report
chines
medic
journal
addit
studi
broadli
provid
insight
improv
uc
suc
treatment
worldwid
conduct
search
chines
period
databas
wanfang
vip
china
nation
knowledg
infrastructur
cnki
august
use
search
term
ulcer
coliti
sever
ulcer
coliti
articl
titl
keyword
result
limit
publish
year
public
exclud
sinc
partial
data
avail
year
number
uc
relat
public
year
defin
wanfang
databas
record
howev
suc
relat
public
download
obtain
inform
public
year
type
topic
studi
design
sampl
size
suc
public
retriev
review
public
classifi
origin
research
articl
case
report
case
seri
review
other
confer
paper
graduat
these
paper
publish
journal
nurs
practic
topic
paper
record
clinic
natur
includ
assess
complex
suc
research
accord
method
describ
scott
et
al
studi
design
clinic
paper
group
one
three
categori
descript
studi
case
report
case
seri
cross
section
studi
observ
analyt
studi
casecontrol
cohort
studi
clinic
trial
proport
total
within
group
compar
everi
period
characterist
patient
treatment
diseas
activ
report
suc
relat
public
record
excel
analysi
statist
analys
perform
use
spss
statist
spearman
rank
correl
coeffici
calcul
studi
trend
time
statist
signific
differ
proport
compar
chisquar
test
pvalu
consid
statist
signific
defin
search
wanfang
databas
retriev
uc
relat
paper
publish
annual
number
public
compar
signific
increas
r
p
shown
figur
almost
half
overal
paper
publish
last
year
determin
tempor
chang
occur
suc
public
repeat
search
process
wanfang
vip
cnki
databas
search
term
sever
ulcer
coliti
articl
titl
keyword
paper
retriev
three
databas
public
year
limit
recent
year
remov
duplic
result
individu
paper
suc
time
shown
figur
fivefold
increas
observ
number
paper
r
p
half
paper
publish
last
year
shown
figur
public
chines
journal
suc
compromis
origin
research
articl
case
report
case
seri
review
confer
paper
graduat
thesi
paper
publish
journal
nurs
origin
articl
report
adopt
diagnost
criteria
suc
diagnost
criteria
consensu
diagnosi
manag
inflammatori
bowel
diseas
develop
revis
chines
societi
gastroenterolog
consensus
suc
diagnos
accord
truelov
witt
criteria
six
bloodi
stool
per
day
plu
least
one
follow
temperatur
puls
rate
bpm
hemoglobin
normal
esr
mmh
sever
uc
judg
accord
truelov
witt
criteria
chines
hospit
consist
criteria
appli
western
countri
includ
origin
research
articl
case
reportscas
seri
analys
complex
suc
research
period
describ
scott
et
al
articl
basic
research
exclud
ensur
articl
includ
studi
clinic
natur
result
paper
classifi
three
group
descript
studi
observ
analyt
studi
clinic
trial
signific
increas
observ
analyt
studi
clinic
trial
especi
recent
year
period
p
figur
proport
descript
studi
decreas
proport
clinic
trial
increas
fold
patient
suc
report
total
paper
suc
number
patient
report
period
present
figur
overal
increas
annual
number
patient
greater
tempor
trend
number
patient
similar
data
number
public
r
p
patient
gender
report
male
femal
result
ratio
malefemal
clinic
manifest
suc
patient
report
articl
blood
stool
abdomin
pain
diarrhea
fever
common
symptom
patient
report
articl
inform
clinic
type
classifi
chronic
recurr
type
chronic
persist
type
initi
onset
type
acut
fulmin
type
articl
record
induc
onset
patient
report
mental
stress
trigger
symptom
physic
strain
improp
diet
infect
patient
without
known
predispos
factor
roughli
estim
incid
seriou
complic
patient
suc
number
case
toxic
megacolon
intestin
perfor
sever
hemorrhag
intestin
obstruct
colorect
cancer
record
respect
colectomi
rate
suc
patient
case
colectomi
report
paper
mortal
rate
calcul
data
sinc
death
report
total
patient
manag
prime
focu
suc
relat
clinic
research
sixteen
observ
analyt
studi
clinic
trial
focus
medic
manag
suc
median
sampl
size
treatment
type
includ
tradit
chines
medicin
corticosteroid
therapi
enter
parenter
nutrit
support
immunosuppress
drug
biolog
agent
probiot
other
figur
adjunct
therapi
tradit
chines
medicin
studi
clinic
trial
effect
rate
rang
articl
report
effect
rate
commonli
use
herb
radix
pulsatilla
radix
scutellaria
rhizoma
coptidi
radix
paeonia
rubra
radix
pueraria
commonli
use
formul
modifi
pulsatilla
decoct
intraven
corticosteroid
treatment
remain
firstlin
therapi
howev
assess
respons
therapi
remain
great
challeng
predictor
predict
indic
failur
steroid
therapi
subsequ
need
colectomi
wide
studi
nine
origin
research
articl
focus
corticosteroid
treatment
patient
suc
receiv
corticosteroid
princip
therapi
three
articl
report
outcom
predictor
therapi
failur
report
outcom
effect
rate
steroid
treatment
rang
pool
effect
rate
previou
sever
attack
onset
stool
frequenc
associ
increas
rate
steroid
failur
predictor
steroid
treatment
failur
includ
stool
frequenc
obviou
bloodi
stool
sever
hypoalbuminemia
elev
platelet
count
intraven
steroid
found
public
research
salvag
therapi
clinic
trial
cyclosporin
avail
retrospect
studi
retriev
includ
cyclosporin
treatment
case
respect
side
effect
report
case
case
hypertens
hepat
dysfunct
hypertrichosi
hyperlipidemia
studi
treatment
efficaci
biolog
agent
casecontrol
studi
random
control
trial
suc
patient
receiv
infliximab
salvag
therapi
result
case
nonrespons
case
transfus
reaction
upper
respiratori
tract
infect
diseas
respons
rate
found
respect
rate
advers
effect
public
search
retriev
origin
research
articl
focus
surgic
manag
suc
patient
suc
patient
receiv
surgic
intervent
studi
two
articl
investig
predictor
need
colectomi
use
oxford
index
swedish
index
edinburgh
index
seo
index
oxford
index
also
known
travi
index
develop
valid
cohort
studi
accord
index
patient
stool
frequenc
per
day
stool
per
day
plu
elev
crp
mgl
day
corticosteroid
therapi
chanc
colectomi
swedish
index
calcul
use
algorithm
number
stool
per
day
x
crp
mgl
score
indic
high
risk
requir
colectomi
edinburgh
index
also
known
ho
score
score
stool
frequenc
point
hypoalbuminemia
mgdl
point
radiolog
evid
colon
dilat
point
sum
score
greater
predict
failur
corticosteroid
therapi
subsequ
need
colectomi
seo
index
calcul
use
mathemat
formula
x
frequenc
bloodi
stool
x
bowel
movement
x
esr
mmh
x
hemoglobin
gdl
x
albumin
gdl
score
greater
predict
need
colectomi
articl
report
either
oxford
swedish
indic
superior
edinburgh
seo
indic
predict
medic
failur
subsequ
need
surgic
intervent
one
articl
report
rate
colectomi
accord
pan
et
al
patient
uc
admit
west
china
hospit
sichuan
china
patient
identifi
sever
diseas
colectomi
rate
patient
five
articl
report
indic
surgeri
includ
medic
refractori
diseas
sever
complic
toxic
megacolon
colon
perfor
massiv
hemorrhag
colorect
carcinoma
six
articl
report
specif
oper
approach
adopt
treat
case
commonli
employ
oper
total
proctocolectomi
ileal
pouchan
anastomosi
ipaa
total
proctocolectomi
ileostomi
total
proctocolectomi
ileoan
anastomosi
iaa
total
colectomi
ileorect
anastomosi
ira
common
late
complic
ipaa
pouchiti
incid
rang
report
articl
two
articl
report
high
frequenc
postsurg
bowel
movement
patient
underw
iaa
per
day
first
month
decreas
per
day
third
month
among
patient
underw
ira
follow
total
colectomi
experienc
diseas
recurr
rectum
howev
case
rectal
dysplasia
andor
cancer
report
median
followup
bibliometr
analysi
wide
use
assess
perform
research
program
institut
andor
countri
research
product
research
influenc
import
bibliometr
indic
measur
number
public
subsequ
citat
perform
bibliometr
analysi
chines
suc
research
use
quantit
qualit
approach
number
public
uc
suc
experienc
signific
increas
year
studi
period
tempor
chang
similar
trend
ibd
public
archiv
pubm
report
weintraub
et
al
may
attribut
increas
preval
uc
improv
diagnost
method
physician
awar
diseas
increas
interest
spread
internet
access
accompani
increas
output
suc
research
also
observ
signific
increas
number
analyt
studi
clinic
trial
complex
studi
design
stronger
term
strength
evid
descript
studi
studi
demonstr
signific
increas
public
output
research
complex
suc
chines
scholarli
journal
impli
correl
increas
preval
uc
suc
diseas
result
subsequ
increas
ucsuc
associ
research
china
tenfold
increas
number
suc
patient
report
chines
medic
journal
recent
year
male
predomin
suc
incid
observ
data
male
femal
ratio
similar
valu
report
multicentr
studi
china
howev
male
femal
patient
report
equal
affect
uc
patient
report
chines
medic
literatur
male
femal
ratio
similar
gender
distribut
diseas
also
note
asian
western
countri
one
hypothesi
observ
male
patient
uc
may
sever
diseas
cours
sinc
male
gender
report
risk
factor
colectomi
detail
populationbas
studi
requir
valid
data
data
also
indic
manag
prime
focu
suc
research
china
sinc
almost
analyt
studi
clinic
trial
found
focu
manag
regim
includ
pharmacotherapi
nutrit
support
surgeri
intraven
corticosteroid
treatment
remain
firstlin
therapi
suc
low
rate
efficaci
report
pool
analysi
consist
high
refractori
rate
report
seah
et
al
prompt
object
assess
failur
steroid
therapi
play
import
role
manag
suc
howev
articl
report
predict
factor
steroid
failur
consequ
hard
obtain
unifi
index
high
sensit
specif
studi
requir
establish
homogen
predictor
unifi
method
predict
steroid
treatment
failur
subsequ
requir
salvag
therapi
surgeri
cyclosporin
infliximab
commonli
use
salvag
therapi
patient
fail
enter
remiss
corticosteroid
treatment
cyclosporin
treatment
improv
outcom
steroidsrefractori
diseas
suc
patient
achiev
immedi
respons
rate
lack
random
control
trial
longterm
followup
studi
focus
cyclosporin
treatment
china
two
retrospect
studi
small
sampl
size
report
high
rate
side
effect
treatment
infliximab
also
report
reduc
colectomi
rate
suc
patient
search
determin
public
infliximab
therapi
chines
suc
patient
appear
studi
regard
infliximab
treatment
report
respons
rate
greater
rate
advers
effect
evid
requir
evalu
benefit
safeti
cyclosporin
infliximab
treatment
chines
suc
patient
tradit
chines
medicin
one
develop
complementari
altern
medicin
approach
use
treatment
ibd
extract
decoct
herb
administr
oral
intak
retent
enema
combin
acid
corticosteroid
therapi
treatment
sever
refractori
uc
underli
mechan
involv
antioxid
antiinflamm
alter
gut
microbiota
studi
half
analyt
studi
clinic
trial
relat
suc
focus
tradit
chines
medicin
report
efficaci
rate
greater
commonli
use
formul
found
modifi
pulsatilla
decoct
proven
attenu
experiment
coliti
mice
inhibit
activ
nuclear
signal
pathway
reduc
product
proinflammatori
cytokin
repair
colon
epitheli
barrier
review
chines
articl
regard
ibd
therapi
also
report
higher
proport
articl
focu
tradit
chines
medicin
less
use
immunosuppress
biolog
agent
although
popular
tradit
chines
medicin
increas
china
western
countri
studi
requir
valid
efficaci
safeti
colectomi
rate
studi
found
colectomi
rate
hospit
suc
patient
report
west
china
hospit
lower
report
unit
kingdom
assum
indic
surgeri
conserv
china
western
countri
unit
kingdom
lower
colectomi
rate
also
report
uc
cohort
asian
countri
like
japan
korea
commonli
employ
oper
total
proctocolectomi
ipaa
sinc
avoid
requir
perman
stoma
lower
risk
diseas
recurr
andor
rectal
carcinoma
excel
longterm
function
result
good
qualiti
life
howev
almost
patient
experienc
pouch
failur
due
pouchiti
pouch
dysfunct
ipaa
incid
pouchiti
rang
review
studi
accord
data
shortterm
mortal
rate
suc
lower
report
western
countri
result
consist
report
wang
et
al
observ
rel
milder
clinic
cours
lower
rate
complic
chines
uc
patient
uc
associ
increas
risk
colorect
cancer
sever
histolog
inflamm
correl
colorect
cancer
risk
incid
colorect
cancer
among
suc
patient
studi
lower
valu
report
wang
et
al
western
studi
respect
studi
requir
confirm
hypothesi
asian
uc
patient
milder
diseas
cours
lower
risk
colectomi
colorect
cancer
mortal
limit
studi
firstli
includ
literatur
publish
perform
bibliometr
analysi
period
public
sinc
includ
sinc
partial
data
public
avail
onlin
databas
search
perform
well
known
mode
treatment
continu
chang
day
day
repeat
databas
search
publish
year
limit
retriev
public
includ
origin
articl
case
report
review
paper
publish
journal
nurs
origin
articl
focus
manag
suc
includ
tradit
chines
medicin
corticosteroid
therapi
immunosuppress
drug
biolog
agent
probiot
increas
articl
biolog
agent
secondli
biolog
agent
wide
suggest
use
develop
countri
studi
found
biolog
agent
prescrib
patient
public
regard
suc
might
due
fact
biolog
agent
infliximab
approv
year
ago
china
kind
medic
expens
patient
met
indic
could
afford
situat
may
chang
passag
time
develop
economi
discuss
biolog
agent
prescrib
frequent
last
two
year
thirdli
review
paper
prime
focu
suc
patient
suc
report
articl
regard
inflammatori
bowel
diseas
might
omit
also
fail
calcul
incid
suc
sinc
studi
epidemiolog
studi
furthermor
total
number
patient
uc
unavail
conclus
studi
document
signific
progress
occur
suc
research
within
chines
medic
research
commun
reflect
increas
output
complex
public
although
tradit
chines
medicin
wide
use
complementari
therapi
suc
rigor
experi
care
analysi
result
experiment
data
requir
valid
benefit
safeti
type
treatment
rel
public
salvag
therapi
suggest
research
efficaci
treatment
cyclosporin
infliximab
chines
suc
patient
requir
report
male
predomin
suc
incid
lower
colectomi
rate
chines
suc
patient
compar
western
countri
base
literatur
review
data
clinic
characterist
obtain
literatur
review
verifi
extend
welldesign
detail
populationbas
studi
sever
ulcer
coliti
suc
potenti
lifethreaten
condit
effect
manag
remain
great
challeng
china
experienc
increas
incid
preval
uc
howev
data
state
suc
relat
research
output
unavail
thu
comprehens
studi
sucrel
chines
public
desper
need
bibliometr
analysi
literatur
review
sucrel
public
chines
period
databas
would
provid
epidemiolog
inform
provid
perspect
research
hotspot
suc
research
perform
china
evalu
number
public
complex
research
design
present
manuscript
bibliometr
analysi
provid
inform
tempor
trend
number
public
chang
complex
research
describ
literatur
review
provid
inform
number
patient
report
year
clinic
characterist
state
manag
suc
patient
studi
provid
inform
use
design
new
treatment
program
suc
patient
worldwid
aim
studi
perform
bibliometr
analysi
determin
tempor
trend
number
chines
public
uc
suc
assess
overal
suc
research
perform
provid
review
data
treatment
type
efficaci
suc
patient
report
chines
medic
journal
studi
provid
understand
current
state
research
output
chines
studi
suc
perspect
research
hotspot
provid
inform
suc
patient
treatment
worldwid
retriev
chines
public
relat
suc
publish
chines
period
databas
wanfang
vip
china
nation
knowledg
infrastructur
number
public
year
record
duplic
remov
topic
paper
record
clinic
natur
includ
assess
complex
suc
research
complex
suc
research
evalu
accord
method
describ
scott
et
al
proport
total
within
group
compar
everi
period
statist
signific
differ
proport
compar
use
chisquar
test
pvalu
consid
statist
signific
number
suc
patient
report
year
clinic
characterist
patient
treatment
efficaci
report
record
analyz
public
regard
suc
publish
chines
medic
journal
number
public
increas
rapidli
signific
increas
found
analyt
studi
clinic
trial
studi
period
research
manag
suc
includ
pharmacotherapi
nutrit
support
well
surgeri
predomin
observ
analyt
studi
clinic
trial
focus
tradit
chines
medicin
littl
research
efficaci
cyclosporin
infliximab
diseas
manag
suc
patient
report
relev
paper
ratio
malefemal
patient
number
patient
report
period
significantli
increas
colectomi
rate
shortterm
mortal
rate
respect
total
proctocolectomi
ileal
pouchan
anastomosi
commonli
employ
oper
studi
document
signific
progress
occur
chines
suc
research
reflect
increas
output
complex
public
avail
research
databas
complex
public
evalu
new
method
describ
scott
et
al
number
patient
report
significantli
increas
inform
clinic
characterist
suc
chines
patient
obtain
literatur
review
verifi
extend
welldesign
detail
populationbas
studi
although
tradit
chines
medicin
wide
use
complementari
therapi
suc
rigor
experi
care
analysi
result
experiment
data
requir
valid
benefit
safeti
type
treatment
research
efficaci
treatment
cyclosporin
infliximab
chines
suc
patient
requir
chines
research
sever
ulcer
coliti
increas
quantiti
complex
accord
bibliometr
analysi
method
previous
describ
scott
et
al
could
use
evalu
complex
public
suc
diseas
also
report
increas
number
suc
patient
male
predomin
suc
incid
lower
risk
colectomi
chines
patient
compar
suc
outcom
worldwid
welldesign
populationbas
studi
requir
valid
result
addit
research
efficaci
treatment
cyclosporin
infliximab
chines
suc
patient
requir
